Pharmaceutical News

RSS

Dyax signs partnership agreement with Sigma-Tau to develop and commercialize subcutaneous DX-88

Dyax Corp. and Defiante Farmaceutica S.A., a subsidiary of the pharmaceutical company Sigma-Tau SpA, announced today a strategic partnership to develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary angioedema and other therapeutic indications throughout Europe, North Africa, Middle East and Russia.

21 Jun 2010

Researchers develop new drugs that relieve cancer pain without side effects

Researchers at the University of Leicester and the University of Ferrara in Italy have collaborated to develop new drugs which have the potential to relieve cancer pain without causing many of the side effects of current pain-treatments like morphine.

21 Jun 2010

Study shows effective and efficient methods for producing recombinant proteins

A shift in the life science market has begun to steer cell culture scientists to re-evaluate their use of native transferrin and iron chelators to pursue recombinant alternatives. Transferrin regulates the uptake, transport and utilization of iron for cellular function, increasing cell growth and productivity. Native transferrin found in bovine or human serum has been widely used in cell culture for these added benefits. However, regulatory issues continue to arise with the use of native transferrin due to blood-borne pathogens.

21 Jun 2010

APP Pharmaceuticals receives FDA approval to market Aztreonam for Injection, USP

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Aztreonam for Injection, USP in two dosage strengths. Aztreonam is therapeutically equivalent to the reference-listed drug Azactam, which is marketed by Bristol-Myers Squibb.

21 Jun 2010

Early-life exposure to PCBs diminishes immune response to diphtheria and tetanus vaccinations: Study

Children exposed to polychlorinated biphenyls early in life later had a diminished immune response to diphtheria and tetanus vaccinations, according to a study published online June 20 ahead of print in the peer-reviewed journal Environmental Health Perspectives. This result suggests that PCB exposure during the first years of life, a critical period in immune system development, could undermine the effectiveness of childhood vaccinations and possibly impair immune system responses to infection.

21 Jun 2010

Exelixis announces regaining of rights to develop and commercialize XL184

Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.

21 Jun 2010

Magic Power Coffee can dangerously lower blood pressure, warns FDA

The U.S. Food and Drug Administration is warning consumers that Magic Power Coffee, an instant coffee product marketed as a dietary supplement for sexual enhancement, contains an active drug ingredient that can dangerously lower blood pressure.

21 Jun 2010

European drug companies' lead in making medicines available to developing countries shrinking: Report

European pharmaceutical companies outcompete their U.S. counterparts in making medicines available to people in developing countries, but their lead is shrinking, according to the second Access to Medicine Index, released today.

21 Jun 2010

Pfizer Canada announces temporary suspension of Lipitor Continuity Card Program

The Regie d'Assurance Maladie du Quebec (RAMQ) recently advised Pfizer that they are examining all pharmaceutical card programs in Quebec. In light of this they have sent us a formal request dated June 16, 2010 to temporarily suspend the Lipitor Continuity Card Program. As part of our ongoing collaboration with the RAMQ, we have made the decision to temporarily suspend the distribution of the Lipitor Continuity Card in Quebec while they complete their analysis.

19 Jun 2010

Boehringer Ingelheim disappointed with FDA Advisory Committee recommendations on flibanserin NDA for HSDD

The Reproductive Health Drugs Advisory Committee met today to discuss the new drug application (NDA) for flibanserin 100 mg as a treatment for Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women. The advisory committee was convened by and makes recommendations to the U.S. Food and Drug Administration (FDA). The FDA will consider the committee's advice as part of its final assessment of the NDA.

19 Jun 2010

DEA, Harvard Drug Group announce agreement to modify suspension

Today, the Drug Enforcement Administration and U.S. Attorney's Office, and Harvard Drug Group announced their agreement to immediately modify the suspension, upon certain conditions, of Harvard's registration to distribute schedule III through V controlled substances out of its Livonia Distribution Center, and a mutual commitment to commence discussions, towards resolution of the issues raised in the DEA's suspension order. The suspension remains as to schedule II controlled substances.

19 Jun 2010

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (Fludase) inhibits infection with multiple human parainfluenza virus strains. DAS181 is a broad spectrum host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness.

19 Jun 2010

Drug-resistant malaria spreading beyond Western Cambodia, U.S. malaria coordinator says

Resistance to artemisinin-based malaria medications seems to be spreading beyond western Cambodia, where it was first detected, U.S. global malaria coordinator Timothy Ziemer said during a visit to the region this week for a conference, Agence France-Presse reports.

19 Jun 2010

USAID pledges $1.2M in support for national polio vaccination campaigns across Central Asia

The United States Agency for International Development has pledged $1.2 million in support for national poliomyelitis vaccination campaigns across Central Asia to fight the first outbreak of polio in the region since 2002.

19 Jun 2010

La Clínica de La Razaa selects Wellpartner to administer 340B Drug Discount Program

Wellpartner, a nationally recognized provider of pharmacy distribution and contract pharmacy services, today announced the addition of La Clínica de La Raza in Oakland, CA, to its rapidly expanding list of community health organization clients. Working with Wellpartner, La Clínica has chosen Safeway as its retail pharmacy partner for this program.

19 Jun 2010

SAHM strongly recommends HPV vaccines for males

On May 28, 2010, the Advisory Committee on Immunization Practices published its guidance for use of the quadrivalent HPV vaccine in males. While noting that the vaccine was approved by the FDA for use in males ages 9 through 26 to reduce their likelihood of acquiring genital warts and that it therefore could be given for this purpose, the statement released by ACIP did not recommend routine HPV vaccination of males.

19 Jun 2010

HBSS reaches $103M settlement with Astra Zeneca

Hagens Berman Sobol Shapiro (HBSS) today announced it has reached a proposed $103 million settlement with Astra Zeneca (AZ) on behalf of consumers and third party purchasers. The class-action lawsuit claimed Astra Zeneca inflated the Average Wholesale Price (AWP), which is used as a benchmark for almost all prescription drug sales in the United States.

19 Jun 2010

Lawmakers want crackdown on drug agreements that keep generics out

Democrats are looking at proposals to crack down on licensing agreements between drug companies that keep generic drugs out of the market, Politico reports. In the agreements, pharmaceutical companies pay generic manufacturers to "delay introduction of generic drugs, which are often cheaper than brand-name drugs.

18 Jun 2010

Advisory panel recommends FDA approve new "morning after" pill

The New York Times: A Food and Drug Administration advisory panel Thursday recommended that the agency approve "a medicine that could help prevent pregnancy if taken as late as five days after unprotected sex. The pill, called ella, sprang from government labs and appears to be more effective than Plan B, a morning-after pill now available over the counter to women 18 and older that gradually loses efficacy after intercourse and can be taken at latest three days after sex.

18 Jun 2010

Walgreens reaches agreement with CVS Caremark on participation in PBM national retail network

CVS Caremark Corporation and Walgreens today announced that the companies have reached an agreement on terms under which Walgreens will continue participating in the CVS Caremark pharmacy benefit management (PBM) national retail network for existing, new or renewal plans. The companies are not disclosing the financial terms of the new contract.

18 Jun 2010

Pharmaceutical News

Dyax signs partnership agreement with Sigma-Tau to develop and commercialize subcutaneous DX-88

Researchers develop new drugs that relieve cancer pain without side effects

Study shows effective and efficient methods for producing recombinant proteins

APP Pharmaceuticals receives FDA approval to market Aztreonam for Injection, USP

Early-life exposure to PCBs diminishes immune response to diphtheria and tetanus vaccinations: Study

Exelixis announces regaining of rights to develop and commercialize XL184

Magic Power Coffee can dangerously lower blood pressure, warns FDA

European drug companies' lead in making medicines available to developing countries shrinking: Report

Pfizer Canada announces temporary suspension of Lipitor Continuity Card Program

Boehringer Ingelheim disappointed with FDA Advisory Committee recommendations on flibanserin NDA for HSDD

DEA, Harvard Drug Group announce agreement to modify suspension

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

Drug-resistant malaria spreading beyond Western Cambodia, U.S. malaria coordinator says

USAID pledges $1.2M in support for national polio vaccination campaigns across Central Asia

La Clínica de La Razaa selects Wellpartner to administer 340B Drug Discount Program

SAHM strongly recommends HPV vaccines for males

HBSS reaches $103M settlement with Astra Zeneca

Lawmakers want crackdown on drug agreements that keep generics out

Advisory panel recommends FDA approve new "morning after" pill

Walgreens reaches agreement with CVS Caremark on participation in PBM national retail network

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News